NASDAQ · Biotechnology

Acurx Pharmaceuticals, Inc. (ACXP) Stock

$1.27 +1.60% NASDAQ: ACXP Healthcare

Valuation

MetricValue
Price$1.27
Market Cap$5.46M
P/E Ratio-0.36
P/B Ratio0.66
P/S Ratio0.00
EPS (TTM)$-5.32
52-Week High$8.34
52-Week Low$1.23
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-124.74%
ROA-68.33%
ROCE-94.08%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity0.00
Current Ratio4.00

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$0$0$0
Operating Profit$-13.0M$-12.0M$-15.0M$-14.0M$-8.0M
Net Profit$-13.0M$-12.0M$-15.0M$-14.0M$-8.0M
EPS$-24.96$-22.36$-23.01$-17.59$-5.32
Op Margin—————

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$13.0M$9.0M$8.0M$4.0M$8.0M
Total Liabilities$1.0M$2.0M$3.0M$3.0M$2.0M
Cash$13.0M$9.0M$7.0M$4.0M$8.0M
Borrowings$0$0$0$0$0

Latest News

Acurx Pharmaceuticals Announces Scientific Poster Presentation of Ibezapolstat's Microbiome Preservation Data in Multiply-recurrent C. difficile Infection PR Newswire · Jul 14, 2026 Acurx Pharmaceuticals to Discuss Second Quarter 2026 Financial Results on August 14, 2026 Conference Call and Provide Business Update PR Newswire · Jul 8, 2026 Acurx Pharmaceuticals Announces Presentation of Results from Leiden University Medical Center Public-Private Partnership for Its DNA pol IIIC Inhibitors at the Leiden Early Drug Discovery & Development (LED3) Scientific Conference PR Newswire · Jun 16, 2026 Acurx Pharmaceuticals (ACXP) Upgraded to Buy: Here's Why Zacks · Jun 8, 2026 Acurx Pharmaceuticals (NASDAQ: ACXP) Highlights FDA's New CDI Guidance That Could Accelerate Approval Path for Ibezapolstat ACCESS Newswire · May 19, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-5.0M$-8.0M$-10.0M$-10.0M$-7.0M
Investing Cash Flow$0$0$0$0$0
Financing Cash Flow$0$0$2.0M$0$0
Net Cash Flow$10.0M$-4.0M$-2.0M$-4.0M$4.0M
Free Cash Flow$-5.0M$-8.0M$-10.0M$-10.0M$-7.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.00
EV / EBITDA0.69
FCF Yield-113.28%
Quick Ratio3.88
Interest Coverage0.00
Return 1Y-79.84%
Return 3Y-95.91%
Return 5Y-98.55%

Ownership

Insiders Held2.99%
Institutions Held6.17%
Institutions Float Held6.36%
Institutional HolderSharesReport Date
Jane Street Group, LLC54,6422026-03-31
Vanguard Capital Management LLC31,0992026-03-31
Geode Capital Management, LLC24,8192026-03-31
Cambridge Investment Research Advisors Inc.20,0002026-03-31
Vanguard Fiduciary Trust Co16,2052026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ADILAdial Pharmaceuticals, Inc $4.04 +1.76% -0.26 $10.61M 0.00%
APREAprea Therapeutics, Inc. $0.58 +4.73% -0.64 $7.24M 0.00%
APVOAptevo Therapeutics Inc. $1.81 +0.56% -0.01 $3.96M 0.00%
BCDABioCardia, Inc. $1.07 +0.94% -1.54 $15.93M 0.00%
BCLIBrainstorm Cell Therapeutics Inc. $0.98 +6.52% -1.04 $10.81M 0.00%

About Acurx Pharmaceuticals, Inc.

Acurx Pharmaceuticals, Inc. is led by CEO David Luci, employs 4 people, headquartered in US, publicly traded since 2021.

Acurx Pharmaceuticals, Inc. (ACXP) stock trades at $1.27 with a market capitalization of $5.46M. The stock is valued at a price-to-earnings (P/E) ratio of -0.36, price-to-book of 0.66, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $1.23 and $8.34, and currently trades 84.8% below its 52-week high.

On profitability, Acurx Pharmaceuticals, Inc. generates a return on equity (ROE) of -124.74%, return on capital employed of -94.08%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

LLY Eli Lilly and Company $1174.49 +0.42% JNJ Johnson & Johnson $261.01 +1.76% ABBV AbbVie Inc. $277.37 +1.82% MRK Merck & Company, Inc. Common Stock (new) $145.82 +2.42% UNH UnitedHealth Group Incorporated Common Stock (DE) $378.36 +2.00% NVS Novartis AG $143.26 +0.10% AZN AstraZeneca PLC $159.37 +0.37% TMO Thermo Fisher Scientific Inc $658.89 +1.06% AMGN Amgen Inc. $415.88 +2.07% GILD Gilead Sciences, Inc. $151.29 +2.85% ABT Abbott Laboratories $99.18 +0.70% NVO Novo Nordisk A/S $38.39 +0.54%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides